MX346095B - Nuevas imidazol-aminas como moduladores de la actividad de cinasas. - Google Patents

Nuevas imidazol-aminas como moduladores de la actividad de cinasas.

Info

Publication number
MX346095B
MX346095B MX2014002832A MX2014002832A MX346095B MX 346095 B MX346095 B MX 346095B MX 2014002832 A MX2014002832 A MX 2014002832A MX 2014002832 A MX2014002832 A MX 2014002832A MX 346095 B MX346095 B MX 346095B
Authority
MX
Mexico
Prior art keywords
modulators
kinase activity
novel imidazole
imidazole amines
amines
Prior art date
Application number
MX2014002832A
Other languages
English (en)
Spanish (es)
Other versions
MX2014002832A (es
Inventor
Bankston Donald
Qiu Hui
R Huck Bayard
Chen Xiaoling
Xiao Yufang
Lan Ruoxi
Celeste Deselm Lizbeth
Neagu Constantin
Charles Victor Jones Christopher
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014002832A publication Critical patent/MX2014002832A/es
Publication of MX346095B publication Critical patent/MX346095B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2014002832A 2011-09-12 2012-09-12 Nuevas imidazol-aminas como moduladores de la actividad de cinasas. MX346095B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533601P 2011-09-12 2011-09-12
PCT/US2012/054900 WO2013040059A1 (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Publications (2)

Publication Number Publication Date
MX2014002832A MX2014002832A (es) 2014-05-27
MX346095B true MX346095B (es) 2017-03-07

Family

ID=46881179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002832A MX346095B (es) 2011-09-12 2012-09-12 Nuevas imidazol-aminas como moduladores de la actividad de cinasas.

Country Status (24)

Country Link
US (2) US9145392B2 (OSRAM)
EP (1) EP2755965B1 (OSRAM)
JP (1) JP5964974B2 (OSRAM)
KR (1) KR101995605B1 (OSRAM)
CN (1) CN104080782B (OSRAM)
AU (1) AU2012308696B2 (OSRAM)
BR (1) BR112014005554A2 (OSRAM)
CA (1) CA2844830C (OSRAM)
DK (1) DK2755965T3 (OSRAM)
EA (1) EA025098B1 (OSRAM)
ES (1) ES2644536T3 (OSRAM)
HR (1) HRP20171554T1 (OSRAM)
HU (1) HUE035019T2 (OSRAM)
IL (1) IL231383A (OSRAM)
LT (1) LT2755965T (OSRAM)
MX (1) MX346095B (OSRAM)
NO (1) NO2791461T3 (OSRAM)
PL (1) PL2755965T3 (OSRAM)
PT (1) PT2755965T (OSRAM)
RS (1) RS56534B1 (OSRAM)
SG (2) SG2014009278A (OSRAM)
SI (1) SI2755965T1 (OSRAM)
WO (1) WO2013040059A1 (OSRAM)
ZA (1) ZA201401013B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347241B (es) * 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
JP2015533181A (ja) 2012-10-16 2015-11-19 アルミラル・ソシエダッド・アノニマAlmirall, S.A. Pi3k阻害剤としてのピロロトリアジノン誘導体
ES2656096T3 (es) 2012-11-16 2018-02-23 Merck Patent Gmbh Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
AU2014228385B2 (en) * 2013-03-11 2018-08-09 Merck Patent Gmbh 6-[4-(1-H-imidazol-2-yl]piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
EP3105224A1 (en) * 2014-02-11 2016-12-21 Merck Patent GmbH Pyrimidine imidazole amines as modulators of kinase activity
EP3205645B1 (en) 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
KR20200093159A (ko) 2019-01-28 2020-08-05 주식회사 링크모션 스마트 팜 모듈 구조물
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
EP1670771A4 (en) 2003-09-30 2010-09-01 Irm Llc COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
WO2005039506A2 (en) 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
KR20060123463A (ko) 2003-12-09 2006-12-01 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 면역 반응을 억제하거나 증식성 장애를 치료하는 방법들
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
WO2006078992A2 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EP2396307B1 (en) 2009-02-11 2014-10-15 Merck Patent GmbH Novel amino azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini

Also Published As

Publication number Publication date
AU2012308696B2 (en) 2017-04-27
SI2755965T1 (sl) 2017-12-29
CN104080782B (zh) 2016-06-01
HUE035019T2 (en) 2018-03-28
IL231383A (en) 2017-11-30
PL2755965T3 (pl) 2018-01-31
BR112014005554A2 (pt) 2017-03-21
RS56534B1 (sr) 2018-02-28
CA2844830C (en) 2019-09-10
DK2755965T3 (en) 2017-09-25
KR20140063694A (ko) 2014-05-27
AU2012308696A1 (en) 2014-02-27
IL231383A0 (en) 2014-04-30
EA201400339A1 (ru) 2014-08-29
EA025098B1 (ru) 2016-11-30
WO2013040059A1 (en) 2013-03-21
US20160000785A1 (en) 2016-01-07
KR101995605B1 (ko) 2019-07-02
ES2644536T3 (es) 2017-11-29
HK1201825A1 (zh) 2015-09-11
SG2014009278A (en) 2014-07-30
JP2014531436A (ja) 2014-11-27
US9145392B2 (en) 2015-09-29
CN104080782A (zh) 2014-10-01
HRP20171554T1 (hr) 2017-11-17
SG10201606301YA (en) 2016-09-29
EP2755965A1 (en) 2014-07-23
NO2791461T3 (OSRAM) 2018-07-21
EP2755965B1 (en) 2017-07-26
LT2755965T (lt) 2017-11-10
ZA201401013B (en) 2018-07-25
CA2844830A1 (en) 2013-03-21
US20140343029A1 (en) 2014-11-20
PT2755965T (pt) 2017-11-02
MX2014002832A (es) 2014-05-27
JP5964974B2 (ja) 2016-08-03

Similar Documents

Publication Publication Date Title
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12017502141A1 (en) Compounds and their methods of use
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MD20150091A2 (ro) Compuşi antivirali
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX2013010016A (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX343377B (es) Carboxamidas azaheterocilcicas de amina ciclica.
PH12015501038A1 (en) Inhibitors of iap
WO2014086453A8 (en) Azaheterobicyclic compounds
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази

Legal Events

Date Code Title Description
FG Grant or registration